# Switching From Semaglutide to Tirzepatide: New 2-Year Data

Source: https://www.dietglp.com/blog/switching-from-semaglutide-to-tirzepatide/
Published: 2026-11-15
Keywords: switching from semaglutide to tirzepatide, switching between semaglutide and tirzepatide, transitioning from semaglutide to tirzepatide, can you switch from semaglutide to tirzepatide, does switching from semaglutide to tirzepatide work, switching from semaglutide to tirzepatide results, switching from semaglutide to tirzepatide after plateau, switching from semaglutide to tirzepatide dosage chart, switching from semaglutide to tirzepatide side effects, how long to wait before switching from semaglutide to tirzepatide, switching from semaglutide to tirzepatide what to expect, changing from tirzepatide to semaglutide, switching from wegovy to zepbound, switching from ozempic to mounjaro

**TL;DR:** Switching from semaglutide to tirzepatide led to more weight loss than staying on semaglutide in a Cleveland Clinic study of 20,486 patients, released November 14, 2026. People who switched between the two drugs averaged 16% weight loss at two years, versus nearly 11% for people who stayed on their first drug and 4% for people who stopped treatment. No label gives a conversion chart, so the starting dose and timing are your prescriber's call. Through any switch, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps your daily protein target and 20-minute workout steady so the weight you lose is fat, not muscle.

Does switching from semaglutide to tirzepatide work, or is it better to stay on the drug you started? **A new Cleveland Clinic study of 20,486 patients found that people who switched between semaglutide and tirzepatide lost about 16% of their body weight at two years, versus nearly 11% for people who stayed on their first drug.** The details matter. Moving from semaglutide to tirzepatide beat staying on semaglutide. Moving the other way did not. The study was released on November 14, 2026, published in eClinicalMedicine and presented at ObesityWeek 2026.

## What the Cleveland Clinic study looked at

Researchers used health records from adults at Cleveland Clinic who had taken semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for at least three months. Then they compared five paths people took next.

A Healio report of the conference abstract adds some background. The average age was about 57. About 63% were women. About two in three had type 2 diabetes, and about 73% had started on semaglutide.

This was not a randomized trial. Nobody was assigned to a path. The team used a method called target trial emulation, which tries to copy a trial using real-world records. It is strong evidence for a records study, but it cannot prove cause the way a trial can.

## Switching results: the five paths at two years

| What people did next | Average weight loss at 2 years |
|---|---|
| Had bariatric surgery | About 28% |
| Switched between semaglutide and tirzepatide | 16% |
| Stayed on their first GLP-1 drug | Nearly 11% |
| Moved to another weight-loss medicine | About 8% |
| Stopped treatment, with no other drug or surgery | About 4% |

Numbers are from the Cleveland Clinic release. The abstract report lists surgery at 26.6%, so treat that row as "roughly 27% to 28%."

The "another medicine" group used older options such as liraglutide (Saxenda), phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave).

Blood sugar followed the same order. Among people with type 2 diabetes, A1C at one year improved most after surgery, then with a switch between the two drugs, then with staying put. People who stopped all treatment saw only small gains in blood sugar and blood pressure.

## Does switching from semaglutide to tirzepatide work better than staying?

In this study, yes, on average. The direction of the switch is the key detail.

| Starting drug | What worked better | Gap at 2 years (abstract report) |
|---|---|---|
| Semaglutide | Switching to tirzepatide beat staying on semaglutide | About 3 kg (6.6 lb) more weight loss |
| Tirzepatide | Staying on tirzepatide beat switching to semaglutide | About 4.5 kg (9.9 lb) more weight loss |

This lines up with the one head-to-head trial. In SURMOUNT-5, 751 adults with obesity took one drug or the other for 72 weeks. Average weight loss was 20.2% on tirzepatide and 13.7% on semaglutide. Our [semaglutide vs tirzepatide guide](/blog/semaglutide-vs-tirzepatide/) walks through that trial, the side effect rates and the prices.

Why are the real-world numbers smaller than the trial numbers? Most people in the Cleveland Clinic study had type 2 diabetes, and people with diabetes tend to lose less weight on these drugs. Real-world patients also miss doses and stay on lower doses more often.

## Switching from tirzepatide to semaglutide

Some people switch this way because of cost, coverage or supply. The study suggests it comes with a trade. People who started on tirzepatide and stayed on it lost about 4.5 kg more at two years than those who moved to semaglutide.

That does not make the switch wrong. Semaglutide still works, and Wegovy has a proven heart benefit on its label. It just means the choice should be made with your prescriber, with the trade in view.

## Is there a switching from semaglutide to tirzepatide dosage chart?

No official one exists. Neither label has a conversion chart, and we will not guess at one. Here is what the labels do say.

| Label fact | What it says |
|---|---|
| Zepbound starting dose | 2.5 mg once a week for 4 weeks, for all uses. Then 5 mg. |
| Dose steps after that | Raised by 2.5 mg after at least 4 weeks on the current dose. Top dose is 15 mg. |
| Using two GLP-1 drugs together | Not recommended. |
| Converting a semaglutide dose | Nothing in the label. |
| A waiting period between drugs | Nothing in the label sections we read. |

So a chart that says "Wegovy 2.4 mg equals Zepbound X mg" is somebody's opinion, not a label. Your prescriber chooses your first dose based on your history and how you handled side effects. For the full label schedule, see our [Zepbound dosage chart](/blog/zepbound-dosage-chart/).

## How long to wait before switching from semaglutide to tirzepatide

The labels give no set gap. Both drugs are weekly shots that leave the body slowly. The Zepbound label puts tirzepatide's half-life at about 5 days, and semaglutide's is about a week. That is why the two should not overlap, and why the day of your first new dose is a medical decision. Ask your prescriber for a date. Do not stop, start or stack these drugs on your own.

## What to expect when you switch

- **Stomach side effects can come back.** Nausea, diarrhea and constipation are the most common side effects of both drugs. They often show up when a drug is started or a dose goes up.
- **Appetite may shift.** Some people feel hungrier for a few weeks while the new drug is at a low dose.
- **Paperwork.** A new drug often means a new prior authorization or a new self-pay price.
- **Protein and workouts should not change.** A switch is a bad time to let eating slide. If nausea returns, small protein-first meals help.

This is where a simple plan earns its keep. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein target and one 20-minute workout a day, plus a Shape Score that shows whether you are losing fat and keeping muscle. It works the same on either drug, so nothing resets when your prescription does. To find your protein number, see our [protein target guide](/blog/protein-target-on-glp1/).

## Switching after a plateau

Many people ask about switching because the scale has stopped. A plateau is normal on every GLP-1 drug, and it does not always mean the drug has failed. Our [plateau guide](/blog/plateau-on-glp1/) covers the common causes and fixes to try first.

If the scale barely moved from the start, genes may play a part. A November 2026 study found rare gene variants that blunt semaglutide more than tirzepatide. Our [GLP-1 non responders guide](/blog/glp-1-non-responders/) explains it.

## What this study cannot tell you

- **It is not a trial.** People who switched may differ from people who stayed, in insurance, health or how they handled the first drug.
- **One health system.** All patients were treated at Cleveland Clinic.
- **Group sizes are not in the release.** We do not know how many people took each path.
- **The starting point is not spelled out.** The release and the abstract report do not say whether weight loss was counted from the first dose or from the day people changed paths. The full paper should settle this.
- **Averages hide a wide range.** Some people do worse after a switch.

## If you have to stop your GLP-1

The clearest message in the study is about the last row in the table. People who stopped with no next step kept the least weight off. Cost, coverage and side effects are common reasons people stop, and they are real.

"When a patient stops a GLP-1 medication, the most important question is what comes next," said co-author Dr. Ali Aminian of Cleveland Clinic.

If you are thinking about stopping, bring that question to your prescriber first. Options in the study included the other GLP-1 drug, an older medicine or surgery. Our guides on [stopping a GLP-1 without regaining the weight](/blog/how-to-stop-glp1-without-rebound/) and [gastric sleeve vs GLP-1](/blog/gastric-sleeve-vs-glp-1/) go deeper on two of those paths.

## The bottom line

Switching from semaglutide to tirzepatide led to more weight loss than staying on semaglutide in a large Cleveland Clinic study, by about 3 kg at two years. Switching the other way gave less. Stopping with no plan gave the least. There is no official conversion chart, so the dose and timing belong to your prescriber. Your part stays the same on either drug: eat enough protein and train your muscles. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) makes that one protein target, one 20-minute workout and one Shape Score a day.

## Sources

- [Cleveland Clinic newsroom, November 14, 2026: Cleveland Clinic Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs](https://newsroom.clevelandclinic.org/2026/11/14/cleveland-clinic-study-identifies-best-treatment-strategies-for-weight-loss-after-stopping-glp-1-drugs)
- [Healio, November 14, 2026: Continued obesity treatment linked to long-term weight loss (ObesityWeek 2026, abstract Oral-021)](https://www.healio.com/news/endocrinology/20261114/continued-obesity-treatment-linked-to-longterm-weight-loss)
- [Zepbound (tirzepatide) prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=zepbound)
- [Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5), NEJM 2025](https://doi.org/10.1056/NEJMoa2416394)


## Frequently asked questions

**Q: Can you switch from semaglutide to tirzepatide?**

A: Yes. Prescribers switch people from semaglutide (Wegovy, Ozempic) to tirzepatide (Zepbound, Mounjaro) often, usually for a plateau, side effects, cost or coverage. You need a new prescription, and you should not take both drugs at once. The Zepbound label says using it with any other GLP-1 drug is not recommended.

**Q: Does switching from semaglutide to tirzepatide work?**

A: On average it did in a November 2026 Cleveland Clinic study of 20,486 patients. People who switched between the two drugs lost 16% of their weight at two years, versus nearly 11% for those who stayed on their first drug. A report of the conference abstract put the edge at about 3 kg more for people who moved from semaglutide to tirzepatide. Results vary by person.

**Q: Is there a switching from semaglutide to tirzepatide dosage chart?**

A: No official one. Neither label has a conversion chart. The Zepbound label lists one starting dose for all uses: 2.5 mg once a week for 4 weeks, then 5 mg. Any chart online that matches a Wegovy dose to a Zepbound dose is not from a label. Your prescriber picks your starting dose.

**Q: How long should you wait before switching from semaglutide to tirzepatide?**

A: The labels do not set a waiting period. Both drugs are weekly shots that leave the body slowly, so the timing of the first new dose is a medical decision. Ask your prescriber which day to start, and do not overlap the two drugs.

**Q: What should I expect when switching from semaglutide to tirzepatide?**

A: Expect a new prescription, a new pen and often a new insurance check. Stomach side effects such as nausea, diarrhea and constipation are common with both drugs and can come back when a new drug is started or a dose is raised. Appetite may change for a few weeks. Tell your prescriber about any severe or lasting symptoms.

**Q: Is switching from tirzepatide to semaglutide a good idea?**

A: In the same Cleveland Clinic study, people who began on tirzepatide lost more weight if they stayed on it than if they switched to semaglutide. The abstract report put the gap at about 4.5 kg at two years. Some people still switch for cost, coverage or side effects. That is a choice to make with your prescriber.

**Q: What if I have to stop my GLP-1 and cannot switch?**

A: The study found that stopping with no other treatment gave the weakest results: about 4% weight loss at two years and only small gains in blood sugar and blood pressure. Other paths in the study were older weight-loss medicines (about 8%) and bariatric surgery (about 28%). Ask your prescriber what comes next before you stop.

